Nova Mentis Life Science Corp
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing natural remedies specifically tailored for individuals on the autism spectrum; health-related foods that promote both mind and body wellness for healthy living, as well as psilocybin clinical trial for fragile X syndrome. The company has collaboration with the University … Read more
Nova Mentis Life Science Corp (NMLSF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.532x
Based on the latest financial reports, Nova Mentis Life Science Corp (NMLSF) has a cash flow conversion efficiency ratio of 0.532x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-78.87K) by net assets ($-148.32K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nova Mentis Life Science Corp - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Nova Mentis Life Science Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Nova Mentis Life Science Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nova Mentis Life Science Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Impera Capital S.A.
WAR:IMP
|
-0.010x |
|
Fibon Bhd
KLSE:0149
|
0.053x |
|
Route 109 Resources Inc.
V:RTE
|
N/A |
|
SWISS RE N (SR9.SG)
STU:SR9
|
0.000x |
|
BR01
F:BR01
|
-0.040x |
|
JS SECURITY TECHN.GRP AB
F:6ZW
|
N/A |
|
Merchant House International Ltd
AU:MHI
|
-0.197x |
|
Medical Marijuana I
PINK:MJNA
|
0.001x |
Annual Cash Flow Conversion Efficiency for Nova Mentis Life Science Corp (2005–2024)
The table below shows the annual cash flow conversion efficiency of Nova Mentis Life Science Corp from 2005 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-299.07K | $-71.77K | 0.240x | -29.91% |
| 2023-12-31 | $-810.60K | $-277.53K | 0.342x | +100.98% |
| 2022-12-31 | $41.34K | $-1.44 Million | -34.917x | -723.68% |
| 2021-12-31 | $459.10K | $-1.95 Million | -4.239x | -2230.65% |
| 2020-12-31 | $4.71 Million | $-856.53K | -0.182x | -29.56% |
| 2019-12-31 | $6.26 Million | $-878.81K | -0.140x | +26.07% |
| 2018-12-31 | $7.24 Million | $-1.38 Million | -0.190x | +61.27% |
| 2017-12-31 | $3.07 Million | $-1.50 Million | -0.490x | +58.25% |
| 2016-12-31 | $653.44K | $-767.37K | -1.174x | +66.88% |
| 2015-12-31 | $199.29K | $-706.63K | -3.546x | +8.15% |
| 2014-12-31 | $126.75K | $-489.28K | -3.860x | -2834.36% |
| 2013-12-31 | $1.28 Million | $-168.36K | -0.132x | -33.57% |
| 2012-12-31 | $1.35 Million | $-133.12K | -0.098x | +28.48% |
| 2011-12-31 | $7.92 Million | $-1.09 Million | -0.138x | +41.33% |
| 2010-12-31 | $2.88 Million | $-675.77K | -0.235x | +22.33% |
| 2009-12-31 | $4.11 Million | $-1.24 Million | -0.302x | -8.48% |
| 2008-12-31 | $1.85 Million | $-514.99K | -0.279x | -15.66% |
| 2007-12-31 | $1.60 Million | $-384.24K | -0.241x | -102.29% |
| 2006-12-31 | $625.79K | $-74.52K | -0.119x | +73.85% |
| 2005-12-31 | $157.44K | $-71.70K | -0.455x | -- |